A Study of SYNT001 in Healthy Volunteers
A Phase 1a, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study of SYNT001 in Healthy Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33014
- Clinical Pharmacology of Miami
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
IInclusion Criteria:
Subjects must meet the following criteria to be included:
- Healthy as determined by comprehensive clinical assessment and clinical laboratory investigations
- Body mass index 18.5 to 30.0 kg/m2
- Must use medically acceptable contraception
- Willingness to complete all study measurements and assessments in compliance with the protocol
Exclusion Criteria:
Subjects meeting any of the following criteria are to be excluded:
- Past or present disease that is judged by the investigator to have the potential to interfere with the study procedures, compromise safety or affect the PK evaluations
- Subject unable or unwilling to comply with the protocol
- Any exposure to an investigational drug within the 30 days prior to screening
- Use of any tobacco or nicotine-containing products
- Abuse of alcohol
- Positive drug test or history of drug abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
single IV infusion
|
|
Experimental: 1 mg/kg
|
single IV infusion
|
|
Experimental: 10 mg/kg
|
single IV infusion
|
|
Experimental: 3 mg/kg
|
single IV infusion
|
|
Experimental: 30 mg/kg
|
single IV infusion
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
assessment of safety data (counts and percentages of adverse events)
Time Frame: Day 0 - Day 28
|
counts and percentages of adverse events
|
Day 0 - Day 28
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetics (serum concentration of SYNT001)
Time Frame: Pre-dose and 0.08, 2, 4, 6, 8, 12, 16, 20, 24, 48, 72, and 120 hours post dose
|
serum concentration of SYNT001
|
Pre-dose and 0.08, 2, 4, 6, 8, 12, 16, 20, 24, 48, 72, and 120 hours post dose
|
|
Pharmacodynamics
Time Frame: Days 1 (pre dose), 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 21 and 28
|
total serum IgG levels
|
Days 1 (pre dose), 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 21 and 28
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- SYNT-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.